Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Phone+49 6132 77 8740
DescriptionVenture Capital Firm



Binger Strasse 173
Ingelheim am Rhein, D-55216, DEU


Vice President


Boehringer Ingelheim Venture Fund

Our primary aim is to activate success for those companies and entrepreneurs we support and to earn a reputation as a long-term trusted partner. Beyond capital investment, we intend to take an active role with our portfolio companies – delivering significant added value through our own extensive drug discovery, scientific and managerial expertise and access to selected relevant experts and knowledge. Nevertheless, we also attach significant importance to confidentiality, establishing ethical walls to protect our portfolio companies and entrepreneurs.

Our sole focus is to search for significant enhancements in patient care through innovative and pioneering science including (but not limited to):

  • Address “undrugable” targets, e.g. targets that are poorly amendable to either current NCEs or NBEs
  • Next generation vaccines, e.g. T-Cell vaccines
  • Next generation NBEs, e.g. cancer immunotherapeutics
  • Regenerative medicine
  • New platforms for Targets and Biomarkers identification

These extend the current therapeutic area focus of Boehringer Ingelheim and demonstrate our commitment to investigate new treatment modalities and technologies, beyond our existing landscape, for the potential future benefit of patients.

Recent Milestones


Company Date Round Size Participants
Amal Therapeutics 2/2014Seed2
Hookipa Biotech 11/2013Series B€20M5
Eyevensys 4/2013Venture Round1
ArmaGen Technologies 11/2012Series A$17M4
Promethera Biosciences 3/2012Series B€23.6M3
Okairos 9/2010Series B$20.5M2



  1. Amal Therapeutics Raises Seed Funding ( [edit]
  2. Hookipa Biotech Raises €20M in Series B Equity Financing ( [edit]
  3. Eyevensys Raises Funds from Boehringer Ingelheim Venture Fund ( [edit]
  4. ArmaGen Technologies, Inc. Announces $17 Million Series A Financing ( [edit]
  5. Promethera Biosciences Raises €23.6M in Series B Funding ( [edit]
  6. Italy's Okairos raises $20.5M for vaccine work ( [edit]
Edit This Page
Last Edited 2/23/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy